Endpoint: Leal Therapeutics raises $30M Series A for schizophrenia and ALS research

“Leal Therapeutics, Inc., a Worcester, Massachusetts-based biotechnology compnay developing new treatments for patients with central nervous system disorders, has secured $30 million in Series A financing. SV Health Investors’ Dementia Discover Fund led the round. Other backers included OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, and PhiFund. Proceeds from the Series A financing will be used to advance LTX-001 through a clinical trial in schizophrenia patients, as well as progress LTX-002 through initial clinical data in ALS.

Find out more about our client, Leal Therapeutics, and its founder, Dr. Asa Abeliovich, here and here.